These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8312047)

  • 21. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.
    Wild C; Greenwell T; Shugars D; Rimsky-Clarke L; Matthews T
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):323-5. PubMed ID: 7786578
    [No Abstract]   [Full Text] [Related]  

  • 22. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide.
    Cilliers T; Moore P; Coetzer M; Morris L
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):776-83. PubMed ID: 16218801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new recombinant virus system for the study of HIV-1 entry and inhibition.
    Roman F; Ammerlaan W; Plesseria JM; Deroo S; Muller CP; Arendt V; Schneider F; Hemmer R; Schmit JC
    J Virol Methods; 2006 Jan; 131(1):99-104. PubMed ID: 16111774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
    D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of human immunodeficiency virus type 1 derived from gp41 transmembrane protein: structure--activity studies.
    Kazmierski WM; Hazen RJ; Aulabaugh A; StClair MH
    J Med Chem; 1996 Jul; 39(14):2681-9. PubMed ID: 8709097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
    Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
    Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
    Kliger Y; Shai Y
    J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enfuvirtide is active against HIV type 1 group O.
    Poveda E; Barreiro P; Rodés B; Soriano V
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):583-5. PubMed ID: 15989465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
    Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigenic variation in HIV.
    Putney SD; McKeating JA
    AIDS; 1990; 4 Suppl 1():S129-36. PubMed ID: 2152557
    [No Abstract]   [Full Text] [Related]  

  • 36. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
    ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.
    Chong H; Qiu Z; Su Y; He Y
    J Med Chem; 2015 Aug; 58(16):6378-88. PubMed ID: 26256053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
    Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.